Imbruvica ibrutinib regulatory update

FDA assigned an April 17 PDUFA date to an sNDA from Pharmacyclics for Imbruvica ibrutinib to treat Waldenstrom’s macroglobulinemia. The Bruton’s tyrosine kinase (Btk) inhibitor is approved in the U.S....